David Nabert, MD
Clinical Cardiac Electrophysiology · Statesboro, GANPI 1174590863
Payments from drug & device makers
Across 283 payments — averaging $25.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- Boston Scientific$962
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$399
- Vital Connect, Inc$383
- Novartis$370
- Atricure, Inc.$354
- plus $2K from 27 others
What the payments were for
- Travel & lodging$6809%
- Food & beverage$6,48890%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 101 | $2,432 |
| Boston Scientific | 14 | $962 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 18 | $399 |
| Vital Connect, Inc | 4 | $383 |
| Novartis | 25 | $370 |
| Atricure, Inc. | 5 | $354 |
| E.r. Squibb & Sons, L.L.C. | 25 | $346 |
| Amgen | 14 | $265 |
| AstraZeneca | 7 | $222 |
| Edwards Lifesciences | 2 | $217 |
| Johnson & Johnson | 13 | $167 |
| Cvrx, Inc. | 6 | $136 |
| Pfizer | 9 | $130 |
| Amarin Pharma, Inc. | 4 | $115 |
| Philips North America LLC | 4 | $92 |
| Boehringer Ingelheim | 6 | $87 |
| Actelion Pharmaceuticals US, Inc. | 4 | $76 |
| Sanofi-aventis U.S. LLC | 3 | $56 |
| Novo Nordisk | 2 | $54 |
| Astellas Pharma US Inc | 2 | $36 |
| Abiomed | 1 | $34 |
| Regeneron Healthcare Solutions, Inc. | 2 | $31 |
| Stryker | 1 | $29 |
| Bardy Diagnostics, Inc. | 2 | $25 |
| Lexicon Pharmaceuticals, Inc. | 1 | $21 |
| Inari Medical, Inc. | 1 | $20 |
| United Therapeutics Corporation | 1 | $19 |
| Medicomp Inc | 1 | $18 |
| Daiichi Sankyo Inc. | 1 | $17 |
| Avinger Inc. | 1 | $17 |
| Merck | 1 | $16 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $14 |
| Baxter Healthcare | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,173 in reported general payments places this provider in the 15th percentile of 93 clinical cardiac electrophysiology providers in Georgia.
See all clinical cardiac electrophysiology providers in Georgia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 461 | $376,588 |
| EntrestoSacubitril/Valsartan | 208 | $176,807 |
| XareltoRivaroxaban | 96 | $70,694 |
| MultaqDronedarone Hcl | 66 | $59,339 |
| FarxigaDapagliflozin Propanediol | 56 | $35,488 |
| JardianceEmpagliflozin | 22 | $21,811 |
| Repatha SureclickEvolocumab | 32 | $17,872 |
| Ranolazine ErRanolazine | 80 | $7,584 |
| VascepaIcosapent Ethyl | 19 | $7,169 |
| Metoprolol Succinate | 442 | $6,059 |
| Flecainide Acetate | 62 | $3,493 |
| Amiodarone Hcl | 282 | $3,061 |
| Ezetimibe | 174 | $2,315 |
| SotalolSotalol Hcl | 69 | $2,261 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 86 | $2,200 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $130 | $376,588461 claims |
| NovartisEntresto | $370 | $176,807208 claims |
| Johnson & JohnsonXarelto | $167 | $70,69496 claims |
| Sanofi-aventis U.S. LLCMultaq | $56 | $59,33966 claims |
| AstraZenecaFarxiga | $222 | $35,48856 claims |
| Boehringer IngelheimJardiance | $87 | $21,81122 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 93 clinical cardiac electrophysiology providers in Georgia.
Other clinical cardiac electrophysiology in Statesboro
- David DelurgioAtlanta$4.2M
- Alok GambhirGainesville$1.7M
- Kent NilssonAthens$1.4M
- David NewtonSavannah$1.4M
- Sandeep GoyalAtlanta$1.3M
- Mikhael El-ChamiAtlanta$1.1M
- Felix SogadeMacon$875K
- Sricharan KantipudiAtlanta$663K
- Anshul PatelAtlanta$615K
- Michael LloydAtlanta$444K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.